expression might be indicative of a definite pathological condition.
In the field of clinical diagnostics, there is increasing interest in endogenous peptides as potentially useful biomarkers. Due to their relatively low molecular weight, peptides show better permeability between tissue compartments as opposed to cell-associated proteases or their respective protein precursors [7] . Consequently, the probability to detect proteolytic fragments of proteins of tissue origin in biofluids is much higher than to detect the protein precursor itself. Endogenous peptides are considered adequate biomarkers for different pathological states and heterogeneity of diseases as they mirror changes in the expression level of their precursor proteins or activity of the corresponding protease. Body fluids including blood, urine, cerebrospinal fluid, synovial fluid and saliva are ideal clinical material for identification of disease biomarkers due to their easy accessibility and peptide-rich content (several thousand native peptides from less than 1 mL). Peptidome biomarkers in human body fluids might thus help in early disease detection, prediction of clinical outcome, monitoring response to a given therapeutic modality, and guiding clinical therapy. A number of peptides have already made their way into the clinic as diagnostic biomarkers, including: Brain Natriuretic Peptide for detecting potential heart failure or assessing the severity of an existing failure; insulin and C-peptide for diabetes; parathyroid hormone, calcitonin and collagen fragments for osteoporosis; pro-gastrin releasing peptide (pro-GRP) for small cell lung carcinoma; β amyloid 1-42 for Alzheimer's disease; and angiotensin II for hypertension [8] .
Although peptides have been the subject of research for several decades, with first successful attempts to analyse their content in diverse clinical samples reported more than 60 years ago, it was only in 2001 when the concept of peptidomics was first introduced in the literature [2, 3, 9] . Continuous advances in mass spectrometry and liquid chromatography (including nano-LC) bringing about significant improvements in sensitivity, accuracy and high-throughput of protein and peptide analyses have contributed to the rapid development of peptidomics and increase in the number of publications in this field over the past decade. Peptidomics has emerged as a complementary tool to proteomics and metabolomics that might facilitate discovery of new drug substances, novel drug targets or new biomarker candidates for specific diseases.
Methodological approaches and experimental workflow in peptidomics
Sample preparation and analytical approaches for peptides differ from those typically used for proteins. Peptidomic workflow usually proceeds via the following steps: (i) sample storage and preparation, (ii) extraction and fractionation of peptide samples, (iii) peptide identification by mass spectrometry, (iv) data processing by bioinformatics tools, and (v) data validation.
Sample collection and storage conditions seem to be important factors in peptidomics analyses. For example, Fiedler et al. [10] showed that differences in collection, sample storage, blood and bacterial interferences, and modes of normalization (creatinine, protein, and pH) of urine samples had significant effects on the variation in the peptide patterns. In particular, the time of urine collection (1st or 2nd morning) significantly influenced the peptide pattern because of the varying concentrations of urine components. Therefore, it is important that collection times be defined exactly for all samples according to the requirements of the clinical study [10] . They also demonstrated that the urine peptide pattern is much more stable at room temperature than peptide analysis of serum. In addition, they detected differences between fresh and once-frozen samples, indicating that the peptide profiles of once-frozen urine samples showed better reproducibility. Similarly, the type of blood collection tube and anticoagulants, variations in clotting time and temperature, storage conditions, and amount of freeze-thaw cycles were shown to influence the serum peptidome profile [11] .
In peptidomics, it is also of utmost importance to hinder proteolysis as to avoid peptide degradation and, importantly, to prevent contaminating the peptide sample with proteolytic fragments of larger proteins from the same biological source [3] . Whereas the proper combination of protease inhibitors can prevent proteolysis in body fluid samples (e.g. blood and saliva), protease inhibitors may not be sufficiently effective in preventing post mortem peptide degradation in tissues such as brain. Different approaches for preventing proteolysis immediately after sampling have been successfully adopted in neuropeptidomics studies, e.g. focused microwave irradiation [12] , protocol using cryostat dissection and a boiling extraction buffer [13] , and tissue stabilization system using a combination of heat and pressure under vacuum [14] .
Another major issue in peptidomics-driven biomarker discovery is the large dynamic range of proteins and peptides in human blood serum/plasma exceeding 10 10 , implying that only the most abundant proteins can be measured by current MS technology [15, 16] . Thus, detection of low abundance serum peptides and small proteins is analytically challenging, and necessitates extensive fractionation procedures prior to mass spectrometric analyses, including immunodepletion of high-abundance proteins, namely albumin and immunoglobulins.
Extraction and separation of peptides and small proteins in complex biological mixtures can be carried out in several different ways: (i) ultrafiltration, which is based on the use of a membrane of particular molecular weight cut-off to filter the sample, whereby the LMW peptides and proteins permeate a membrane while the large proteins are retained; (ii) organic solvent precipitation, where the addition of organic solvents (e.g. acetone, acetonitrile) causes high molecular weight proteins to precipitate whereas low molecular weight peptides and small proteins are retained in solution; and (iii) solidphase extraction (SPE), which is based on the use of solid materials (e.g. nonpolar (C-8, C-18) or polar (-CN, -NH 2 )) to selectively bind and retain peptides from complex biological samples [4] . Magnetic beads are also used for capture and selective enrichment of peptides. These particles bearing immobilized affinity or hydrophobic ligand or ion-exchange groups are mixed with the sample, and after the incubation period, during which peptides bind to the magnetic particles, the whole magnetic complex is removed from the sample by a magnetic separator, and then a series of washing steps is carried out to remove the contaminants followed by elution of peptides from the magnetic beads using conventional elution methods such as the change of pH, change of ionic strength, use of polarity reducing agents or deforming eluents containing chaotropic salts [17] . Furthermore, restricted access material (RAM) has been described for the separation of large biomolecules and the extraction of LMW peptides and proteins. It is based on the use of particles whose outer surface is coated with nonadsorptive hydrophilic packing, while the surface of the pores can be covered with different affinity matrices [18] . Basically, the process resembles that of size exclusion as proteins are prevented from accessing the bonded phase in the pores, while simultaneously retaining low molecular weight compounds (peptides and small proteins) on the affinity matrix in the pores.
The most popular method for peptide separation is liquid chromatography, in particular reversed-phase and ion-exchange chromatography, which is usually coupled to mass spectrometry. Two most common types of mass spectrometers for peptidomics studies are quadrupole time-of-flight (Q-TOF) and ion trap (IT) instruments [19] . Capillary electrophoresis-electrospray-mass spectrometry (CE-MS) has recently gained in popularity due to its high efficiency, fast analysis time, low consumption of sample and reagents, and versatility related to different CE modes that are available [20] . Currently, the most commonly used interface for CE-MS is electrospray, because this soft ionization method makes it easy to directly transfer the analytes from CE to MS and close the electrical circuit indispensable for CE to work successfully. Three CE separation modes currently exist for the analysis of peptides: 1.) capillary zone electrophoresis (CZE, also called free solution capillary electrophoresis); 2.) capillary electrochromatography (CEC); and 3.) capillary isoelectric focusing (CIEF). CZE is the most popular CE mode for CE-MS analysis of peptides. In CZE, peptides are resolved according to their different charge/mass ratios selecting MS compatible background electrolytes (BGE) usually composed of formic acid, acetic acid and/or ammonium hydroxide [20] . In CIEF, peptides are separated based on their pI values in a pH gradient formed by carrier ampholytes by applying high electric voltage. CEC is an hybrid technique that integrates the features of HPLC and CE, and separation of analytes is carried out in a way similar to HPLC, but the driving force is, in this case, the electroosmotic flow. CE-MS is particularly suited for biomarker discovery studies due to its high sensitivity (detection limit in the low fmol to amol range) and reproducibility, which enables the reliable analysis of more than 800 different peptides in body fluids such as cerebrospinal fluid with molecular weights ranging from 0.8 kDa to about 20 kDa [21] .
An approach for the visualization and analysis of peptides and small proteins referred to as differential peptide display (DPD) has shown as promising strategy in discovering novel disease biomarkers and drug candidates [22] . In this method, peptides extracted from clinical samples are separated into fractions using highresolution reversed-phase chromatography, and each fraction is analysed by matrix-assisted laser desorptionionization-time-of-flight (MALDI-TOF) mass spectrometry [23] . Following statistical processing, peak recognition and visualization, the single spectra are combined to create a virtual two-dimensional diagram that serves as a peptide mass fingerprint containing quantitative and qualitative information. Around 1000-5000 components ranging from 0.5-15.0 kDa are visualized and defined by the three dimensions: (1) chromatographic fraction number; (2) mass per charge ratio; and (3) intensity from MS data [24] . By overlaying two maps of different biological origin (e.g. malignant and normal cells), a subtractive map is obtained from which differences in peptide patterns can be read out. Subsequent sequencing of selected peptides by means of electrospray ionization quadrupole timeof-flight mass spectrometry (ESI-qTOF-MS) allows their identification [25] .
Unlike proteins, which are cleaved into peptides by trypsin and identified by comparison of resulting cleavage pattern with available databases, peptides are identified by their characteristic fragment pattern obtained after fragmentation in MS-MS experiments [26] . However, peptide identification represents greater challenge than protein identification due to limited availability of peptide mass fingerprint information. Sequencing is hampered by several obstacles associated with MS sequencing of naturally occurring peptides: tryptic digests cannot be used because of a loss of connectivity to the original identification parameters [27] . Major obstacles include suboptimal use of proteomics search engines, such as MASCOT or the open mass spectrometry search algorithm, for naturally occurring peptides, as well as the chemical nature (e.g. post-translational modifications) of the peptides that prevents successful sequencing [27] . In addition, MS/MS experiments frequently produce a limited number of preferred fragmentation products (at proline residues, carbohydrate side-chains, etc.) [28] . Tandem MS sequencing of endogenous peptides in their native form can additionally be challenging because they show size heterogeneity and contain multiple internal basic residues, the characteristics not found in peptide fragments produced by in vitro digestion [29] .
Identification and structural characterisation of peptides and proteins depends not only on accurate mass measurement of molecular ions but also on fragmentation capability of mass spectrometer. The most common fragmentation technique is collision-induced dissociation (CID), a technique based on electron transfer and dissociation of the precursor ion through collision with an inert gas molecules in the collision cell, predominantly giving rise to N-and C-terminal peptide fragments (the so called b and y ions) as the amide backbone bonds (C-N) dissociate [30] . In addition, two recently developed fragmentation approaches, electron capture dissociation (ECD) and electron transfer dissociation (ETD), have proved valuable in sequencing large peptides and small proteins. In both techniques, charge reduction of multiply charged peptide ions takes place via electron transfer, followed by unimolecular dissociation of the resulting activated species giving rise to fragments of the peptidic backbone [31, 32] . This electron transfer yields an oddelectron molecular species whose cleavage of the N-C α backbone bonds leads to generation of c and z fragment ions. Compared to CID, ECD and ETD preserve labile posttranslational modifications (e.g. phosphorylation) and allow direct mapping of peptide/protein modifications [33, 34] . CID and ETD/ECD generate complementary sequence information, and use of CID in conjunction with either ECD or ETD enables more reliable peptide sequence identification [35] .
Mass spectrometry-based quantitative peptidomics has emerged as a powerful strategy to screen clinical samples in order to identify new disease biomarkers, and has become an indispensable tool in biomarker discovery. One methodological approach in quantitative peptidomics is based on the use of stable isotope peptide labelling or mass tagging. This approach allows the comparative quantitation of peptides between two different samples. Peptides originating from two different samples are uniquely labelled with isotopically heavy and light atoms to acquire a different isotopic or chemical signature, combined, fractionated by multidimensional chromatography and analysed by LC-MS/MS [36] . Light and heavy forms of individual peptides have the same amino acid sequence and are chemically identical (they behave in the same way during separation steps and ionization process in MS), but differ in mass by the weight of the isotopic label [7] . Relative quantification is accomplished by comparing the peak intensities of the heavy and light peptides to determine the relative abundance of the same peptide between two different samples. There are several methods for the incorporation of mass tags into peptides including: (i) metabolic labelling based on the use of heavy amino acids that incorporate into nascent proteins during the processes of cellular metabolism and protein biosynthesis (e.g. stable isotope labelling by amino acids in cell culture, SILAC [37] ), (ii) chemical labelling based on the use of chemical reactions to introduce an isotopic or chemical tag at specific functional groups on polypeptides (e.g. cysteine thiols in the isotope-coded affinity tag (ICAT) method [38] ; or N-termini and lysine side chains of peptides in the isobaric tags for relative and absolute quantitation (iTRAQ) method [39] ; and (iii) enzyme-mediated isotope incorporation (e.g. 18 O labeling) [40] .
Second approach in quantitative peptide measurement is label-free quantitative peptidomics, which has garnered interest amongst scientists due to low finical costs, short sample preparation time, easy implementation and unlimited number of samples that can be compared. In this approach, each sample is prepared separately and subjected to individual LC-MS/MS analyses. Peptide quantification is generally based on two strategies: (1) measuring and comparing mass spectral peak intensities of peptide precursor ions that belong to a particular protein; and (2) counting and comparing the number of the MS/MS spectra identifying peptides of a given protein [41] .
Selected reaction monitoring (SRM), also called multiple reaction monitoring (MRM), has become the method of choice for targeted protein/peptide quantification and biomarker validation [42, 43] . The major advantage of this approach includes linear response over a wide dynamic range, up to five orders of magnitude, which facilitates detection of low-abundance proteins in complex mixtures [44] . This highly selective and sensitive method is commonly performed on triple quadropole mass spectrometer, and does not require full mass spectra to be recorded. In SRM/MRM, the first and the third quadrupoles act as static mass filters to specifically select predefined m/z values corresponding to the precursor ion (ionized peptide of interest) and a specific fragment ion of a selected precursor ion, whereas second quadrupole acts as collision cell. The specific pair of m/z values correlating a product ion (fragment ion) with that of its precursor is known as a transition [44] . Multiple transitions can be monitored sequentially within a measurement cycle. In a typical MRM experiment, a stable isotope-labelled synthetic peptide (analogue to the target analyte) acts as internal standards for specific peptides is spiked into the sample matrix, and the mass spectrometer is set to scan only for the diagnostic fragment ions of both the analyte and the spiked compound [7] . Quantitation is carried out using the relative response of the spiked compound to the target analyte. For successful SRM, several steps are extremely important including selection of target proteins and selection of peptides with good MS responses and the ability to uniquely identify the target protein [45] .
Peptide profiling in cancer research

Identification of biomarkers for cancer diagnosis
Peptides as proteolytic reaction products reflect the changes of enzymatic activity of specific proteases (matrix metalloproteinases and cathepsins), which are linked with tumour cell growth, invasion, angiogenesis and metastasis. Peptides which are released from cancer cells are present in low concentration, since marker derived from tumour tissue will be dramatically diluted on its way into the bloodstream. Therefore, the likelihood for identification of tumour biomarker is closely associated with concentration of the biomarker and the sensitivity of the detection method. Several previous studies clearly demonstrated the capability of peptidomics technologies to detect specific cancer biomarkers for early disease detection or prognosis. For example, Ueda et al. [46] subjected 92 heat-inactivated serum samples (30 and 62 from healthy controls and lung adenocarcinoma patients, respectively) to peptide enrichment by gel filtration chromatography, producing peptidome fractions with molecular weight of 1000-5000, which were further analysed with nano-LC/MS-MS. After data processing and label-free quantification analysis, candidate biomarkers were validated by MRM using new 96 serum samples. This study revealed changes in serum levels of 118 peptides between control and lung cancer groups, among which APOA4 (apolipoprotein A-IV) 273-283, FIBA (fibrinogen α) 5-16 and LBN (limbin) 306-313 fragments were highlighted as clinically useful biomarkers for both early detection and tumour staging of lung cancer [46] .
Another bright example of how peptidomics can deliver new biomarkers that can be potentially implemented into a clinically useful screening procedure for monitoring cancer is provided by the study on stomach cancer carried out by Cohen et al. [47] . They performed serum peptidome profiling of control subjects and stomach cancer patients at various clinical stages. Using bioinformatics tools, the authors were able to identify peptide patterns that distinguish between stomach adenocarcinoma patients and cancer-free controls. MALDI-TOF mass spectrometry analysis resulted in the discovery of 9 signature peptides, and three of them were identified as fragments of Apolipoproteins C-I and C-III. Quantitative validation in additional serum samples from 142 subjects using commercial clinical assays confirmed the findings from the mass spectrometry analysis, and proposed for the first time serum apoC-I and apoC-III as potential biomarkers for stomach cancer.
Most peptides and smaller proteins (<60 kDa) in serum bind to high-abundance proteins such as albumin, which acts as a carrier and transport protein within the blood and protects these low-molecular weight species from clearance by kidneys allowing them to remain in circulation. Although serum protein depletion methods are effective in terms of removing high-abundant proteins and broadening analytical window for detection of the species present in low concentrations, they also bear potential risk of concomitant removal of many important LMW proteins or peptides which are bound to albumin (e.g. hormones and cytokines). Fredolini et al. [48] have come up with an innovative methodological approach to get rid of abundant carrier proteins in human serum such as albumin without the concomitant loss of small proteins and peptides, with the aim to discover biomarkers for early detection of ovarian and prostate cancer. This novel peptidome enrichment technology was based on the core-shell hydrogel nanoparticles for rapid and simple concentration of protein fragments and small protein molecules. The core shell particles were composed of a sieving shell and a core containing the bait. The latter was comprised of the high-affinity dye molecules (acrylic acid affinity capture reagent) that compete with albumin for the binding of low-molecular weight cationic proteins and peptides, which are thus captured within the particle. The shell serves as a sieve which prevents entrance of high-molecular weight proteins (>30 kDa) present in high concentrations in serum. Obtained peptide fractions were further analysed by LC-MS/MS followed by data analysis. Label-free quantitative analysis based on spectral counting method was applied revealing increased relative abundance of 14 proteins in the serum of pre-prostatectomy patients compared to the post-prostatectomy patients, and 59 proteins in the serum from early-stage epithelial ovarian cancer patients in comparison with benign gynecologic control group [48] . Importantly, integrin α-2b preproprotein, leucine-rich alpha-2-glycoprotein-1 and lipopolysaccharide-binding protein precursor have been identified as proteins whose levels were elevated uniquely in ovarian cancer. The potential of specific expression profiles of LMW peptide fragments of integrin as tumour progression markers for prognostic and diagnostic purposes were proposed for validation in additional studies in larger patient population. As for differentially abundant peptides and LMW fragments found specifically in prostate cancer, some of them hold great clinical potentials including vitronectin and cadherin 1 type 1 (E-cadherin), cell adhesion proteins with previously proven involvement in prostate cancer progression and metastasis [49] [50] [51] , and their presence in the blood points to the local loss of diffusion barriers, i.e. cell junction and the basement membrane [48] .
Several studies put forward peptidome profiling as a useful tool for improving diagnosis of pancreatic cancer in combination with common clinical markers of pancreatic cancer. For example, Fiedler et al. [52] performed comprehensive peptidomics study of sera from patients with pancreatic cancer and healthy controls based on peptidome separation and fractionation with magnetic beads bearing different surface properties (immobilized metal ion affinity chromatography, hydrophobic interaction and weak cation exchange) and MALDI-TOF MS analysis. They identified and validated platelet factor 4 as a new discriminating peptide marker in pancreatic cancer. In the authors' view, the additional application of this peptide strongly improves the diagnostic power of commonly used serum tumour marker panel comprising of CA 19-9 and CEA, which might have additional implication in differential diagnosis of pancreatic cancer and pancreatitis [52] . Similarly, Zapico-Muñiz et al. [53] developed standardised protocol to analyse peptidome profiles of human serum for detection of pancreatic cancer. Serum peptides were extracted using immobilized copper ion chromatography followed by MALDI mass spectrometry analysis. The authors reported that the diagnostic sensitivity was 89.9%, and the diagnostic specificity was 92.7%, using two serum features and CA 19-9 serum concentration. By using this approach, the authors were able to distinguish between healthy controls and patients with pancreatic cancer and chronic pancreatitis, with the use of three features of the peptidome (diagnostic sensitivity, 98.2%; diagnostic specificity, 97.1%) [53] .
As evident from the abovementioned and other similar studies, serum peptidome patterns hold great diagnostic potentials as they were shown to have good discriminatory power for distinguishing between benign and malignant disease in other cancer types as well including esophageal squamous cell carcinoma [54] , breast cancer [55] , colorectal cancer [56] , renal cell carcinoma [57] , hepatocellular carcinoma [58] , gastric cancer [59] , non-small cell lung cancer [60] and metastatic thyroid carcinomas [61] .
In addition to serum, other body fluids have been explored as potential source of cancer biomarkers. For example, Chang et al. [62] performed peptidomics analysis of gastric juice samples by MALDI-TOF-MS to identify gastric cancer biomarkers. Their study showed decreased levels of pepsinogen and leucine zipper protein fragments and increased levels of albumin peptide fragments and α-1-antitrypsin fragments in gastric juices from patients afflicted with gastric cancer, and put forward these peptides as potential diagnostic markers for gastric cancer. In particular, the study revealed that that the sensitivity and specificity of even a single peptide as a biomarker for gastric cancer detection are still significantly higher than those of clinically used serological biomarkers for gastric cancer, namely CEA and CA19-9 [62] .
Cerebrospinal fluid was also shown to be rich source of biomarkers in the study carried out by Schuhmann et al. [63] , who used differential peptide display technology to identify markers of glioblastoma multiforme (GBM). Their study identified four out of more than 2000 detected peptides cleaved from different protein precursors that were significantly elevated in CSF of GBM patients as compared to normal controls including C-terminal fragments of alpha-1-antichymotrypsin, osteopontin, transthyretin and N-terminal residue of albumin. These peptides can be ascribed to different molecular aspects including tumour cell metabolism, induced changes in protease activity, induced functional changes of brain barriers, or an altered elimination. However, the possibility to use these peptides as potential markers for initial diagnosis of malignant glioma, early recognition of disease recurrence or monitoring the efficacy of adjuvant therapy protocols has yet to be determined.
Cancer treatment
Besides its usefulness in identifying potential diagnostic biomarkers, peptidomics may help guide therapy for cancer patients. In particular, it has proved an effective approach to identify treatment regimens to which the tumour is susceptible, as demonstrated by Voortman et al., [64] who carried out peptide profiling of serum samples from advanced non-small cell lung cancer patients treated with first-line chemotherapy consisting of cisplatin and gemcitabine, as well as bortezomib. The results obtained therein revealed that a 6-peptide ion signature discriminates between the patients with a shorter overall survival in comparison with longer overall survival of the patients after treatment with 82% accuracy, sensitivity and specificity. In addition, the authors detected a 5-peptide ion signature that could distinguish patients with a partial response to treatment in comparison with non-responders with 89% accuracy at 100% sensitivity and 83% specificity [64] . Specific serum peptide patterns were also detected that could separate NSCLC patients from cancer-free control subjects.
Peptides present at the cell surface that are bound by HLA class I molecules are recognised by CDB T lymphocytes and play important roles in tumour biology. Revealing the identity of HLA-associated peptidome is paramount in understanding interactions between tumour cells and immune system, and may foster development of new treatment modalities for tumours in which current therapies show low efficacy, e.g. glioblastoma multiforme, a devastating brain cancer that typically results in death in the first 15 months after diagnosis. Dutoit et al. [65] showed that peptides presented by glioblastoma multiforme (GBM) cells in vivo are valuable source of multiple tumour antigens that may be exploited in cancer immunotherapy. Using comprehensive LC-MS analysis of HLA/peptide complexes isolated from ex vivo HLA-A*02 + glioblastoma multiforme samples, they identified over 6000 HLAbound peptides among which more than 3000 were restricted by HLA-A*02 [65] . Additional selection of the most promising candidates based on high messenger RNA over-expression in GBM and potential implication in gliomagenesis followed by in vitro evaluation of these peptides for their ability to precipitate strong T cell responses in peripheral blood mononuclear cells from HLA-A*02+ healthy individuals led to the selection of 10 most immunogenic peptide candidates. These peptides were abundantly expressed in the large majority of the GBM samples analysed ex vivo, but poorly or even not expressed in normal brain and non-CNS tissues. Importantly, 9 of the 10 peptides have been developed in a multipeptide therapeutic vaccine designated IMA950, which is currently in phase I clinical trials. As exemplified by this study, the potentials of peptidomics to boost clinical translation have already become evident.
Status of estrogen receptor is considered a major biomarker for the classification of breast cancer with a prominent role in prognosis and therapy choice for these patients. Breast cancers that have a large number of estrogen receptors (ER), classified as ER+ tumours, can be treated with hormone therapies such as tamoxifen and aromatase inhibitors. In addition, ER+ tumours are often linked with a better survival than tumours with few or no estrogen receptors (ER-tumors). The capacity of peptidomics to discern specific molecular signatures indicative of ER functionality was confirmed in the study by Traub et al. [66] , who studied peptide profiles of invasive breast cancer with positive and negative ER status using differential peptide display technology based on the offline-coupled combination of reversed-phase-HPLC and MALDI mass spectrometry. They found thymosin α-1, an asparaginyl endopeptidase-generated cleavage product of the ubiquitous acidic protein prothymosin α, to differentiate the tumour samples according to their receptor status with the highest specificity. In addition, thymosin α-1 was over-expressed in estrogen-negative breast cancer tissues and its concentration was downregulated in estrogen-positive breast cancer samples. The authors proposed that detection of thymosin α-1 in ER+ breast cancer may point to steroid-insensitive breast cancers or breast cancers with compromised response to regular steroid stimulation. Therefore, the analysis of thymosin α-1 in combination with ER status could be potentially used in stratification of the patients likely to benefit from anti-estrogen therapies or of those that require more intensive treatment [66] .
Peptidomics for early diagnosis of neurodegenerative diseases
Neurodegenerative diseases (NDD) can be generally considered as hereditary and sporadic conditions characterised by progressive nervous system dysfunction. These diseases are often accompanied by atrophy of the affected central or peripheral structures of the nervous system. Proteolysis is the primary mechanism that drives development of major neurodegenerative disorders including Alzheimer's, Huntington's and Parkinson's disease. Production of neurotoxic peptides is commonly found in all these disorders. For example, amyloid-beta (Aβ) peptides are involved in the formation of amyloid plaques in the brain, one of the major biochemical hallmarks of Alzheimer's disease (AD). These peptides, which are produced by the cleavage of a transmembrane amyloid precursor-protein (APP) with two enzymes, β-and γ-secretase, are linked with impaired neuronal function and memory characteristic for AD patients. In Huntington's disease, N-terminal fragments of mutant huntingtin protein are major components of aggregates found in human post-mortem brain. Moreover, several studies also showed alterations in the level of many other different peptides in NDD such as cholecystokinin, vasoactive intestinal polypeptide and neuropeptide Y in cerebral cortex of Huntington's disease patients [67] , and neuropeptides Met-and Leu-enkephalin (MET-ENK, LEU-ENK), substance P and neurotensin in postmortem samples of basal ganglia from Parkinson's disease patients [68] . Thus, global peptidome profiling may help identify novel molecular determinants of neurodegeneration, which could set new direction in the management of NDD patients.
Biomarkers might have an important role in different aspects of NDD research including development of more effective and accurate diagnostic tools and indication of disease severity that would provide the basis for development of putative disease-modifying drugs for NDD [69] . In particular, biomarkers can prove useful in studies determining drug dosage, toxicity, pharmacology and efficacy. Many neurodegenerative diseases share some common clinical symptoms and can be hardly differentiated, particularly at early stages. Biomarkers would help discriminate between different forms of dementia, which could guide clinicians in making decisions regarding treatment and monitoring of disease progression. Although there are numerous reports on proteomics studies into pathogenesis of different neurodegenerative diseases, data on global peptidebased biomarker discovery for this group of diseases are rather scarce. For this reason, our review would focus on available literature data which is currently limited to only two neurodegenerative diseases, namely Alzheimer's disease and Creutzfeldt-Jakob disease.
Alzheimer's disease
Alzheimer's disease (AD) is the most common cause of dementia among older people that affects millions of individuals worldwide. Its high incidence is best illustrated by the report from 2013 Alzheimer's Disease Facts and Figures, a statistical resource for US data related to Alzheimer's disease, which revealed that an estimated 5.2 million Americans have had AD in 2013 [70] . This includes an estimated 5.0 million people age 65 and older, and approximately 200,000 individuals younger than age 65 who have younger onset AD. Management of AD patients is significantly hampered by the lack of simple and reliable tests that would diagnose this disease in its early stages. Currently, the most definitive diagnosis of AD can only be established by post-mortem histopathological brain examination. Furthermore, there is no therapy available today that would effectively slow or stop the death and malfunction of neurons in the brain that cause AD symptoms and make this disease fatal.
Wijte et al. [69] carried out differential peptidomics analysis of post-mortem cerebrospinal fluid of neuropathologically confirmed Alzheimer's disease patients and non-demented controls. Peptide enrichment was performed by novel organic phase extraction procedure employing methanol and chloroform, which gave rise to free unbound peptides (unbound peptide fraction) and peptides released from the non-covalent complexes with abundant CSF proteins (protein-bound peptide fraction), which were further analysed by MALDI-TOF MS. The authors observed striking differences in the CSF peptide profiles between AD patients and nondemented controls for the both peptide fractions. Further mass spectrometric identification of differential peptides by the authors revealed VGF nerve growth factor inducible precursor and complement C4 precursor in the unbound peptide fraction, which displayed high correlation with AD. As for protein-bound fraction, discriminative peptides were VGF nerve growth factor inducible precursor and α-H2-glycoprotein derived peptides. A particularly interesting finding was an alteration in the α-H2-glycoprotein glycosylation. Thus, one of the glycosylated peptides of α-2-H2-glycoprotein was down regulated (m/z 3453), whereas the O-linked HexNAc1Hex1 peptide of α-2-H2-glycoprotein (m/z 3162) remained constant in both diagnostic groups [69] . Although previous studies have reported on aberrant protein glycosylation in AD [71, 72] , the role of α-H2-glycoprotein glycosylation in development of neuropathological hallmarks of AD has yet to be explored.
The discriminating power of fragments of the neuroendocrine protein VGF for AD was also confirmed in two additional independent studies. For example, Selle et al. [73] applied differential peptide display technology to analyse CSF samples from AD patients, cognitively unimpaired subjects and from patients suffering from other primary dementia disorders: the study revealed 12 candidate biomarkers that were identified using mass spectrometry as fragments of the neuroendocrine protein VGF and another one as the complement factor C3 descendent C3f.
Similarly, Jahn et al. [21] set out to develop a new method for the differential diagnosis and identification of new peptide biomarkers of Alzheimer's disease using capillary-electrophoresis coupled to mass-spectrometry to analyse cerebrospinal fluid samples obtained from patients suffering from Alzheimer's disease and frontotemporal demenatia versus cognitively healthy controls. Using this approach, the authors managed to detect 1104 low-molecular-weight peptides. Importantly, they identified discriminative biomarker pattern for AD based on 12 discriminatory peptides. This AD pattern was subsequently tested in additional prospective collected samples of 100 subjects, where AD was diagnosed with a sensitivity of 87% and a specificity of 83%. Importantly, the authors showed that diagnostic power of AD-specific peptide patterns in terms of sensitivity and specificity for AD diagnosis was in the range of that achieved by combined application of common clinical tests such as β-amyloid1-42, total-tau and phospho 181 -tau [21] . Sequence analysis of biomarkers of AD peptide panel revealed fragments of neurosecretory protein VGF, phospholemman (FXYD1), clusterin (apolipoprotein J), chromogranin A and proprotein convertase subtilisin/ kexin type 1 inhibitor (pro-SAAS).
Creutzfeldt-Jakob disease
Creutzfeldt-Jakob disease (CJD) is a rare degenerative, invariably fatal brain disorder that affects about one person in every one million people per year worldwide. It is characterised by rapidly progressive dementia. The onset of symptoms occurs at age of 60 in average, and approximately 90% of patients die within one year. This extremely devastating disease is initially manifested by failing memory, behavioural changes, lack of coordination and visual impairment. Advanced stages of this disease are marked by pronounced mental deterioration, blindness and muscle weakness, and these patients often enter a coma. Current scientific theory that accounts for the occurrence of CJD is based on prion proteins as causative factors of the disease. Prion proteins can occur in two forms, normal, harmless form found in the body's cells, and infectious form causing CJD. Difference between these two forms lie in the conformation, as the infectious form assumes abnormal three-dimensional shape. This misfolded prion protein destroys brain cells in an as yet unexplained process.
Currently, there is no single diagnostic test for CJD. Some symptoms of CJD can be similar to symptoms of other progressive neurological disorders such as Alzheimer's disease, and the only reliable way to confirm a diagnosis of CJD is by brain biopsy or autopsy and demonstration of the pathological isoform of the prion protein (PrP Sc ) in CNS. Peptidomics may provide an entry point for the development of novel diagnostic strategies for CJD, as demonstrated by Chen et al. [74] who carried out mass spectrometry-based profiling of the peptides ranging from 1-10 kDa in CSF samples pooled from probable sporadic CJD and non-CJD patients. In this study, the CSF samples of 40 probable sporadic CJD (sCJD) patients, 32 non-CJD cases with dementia and 17 non-CJD cases without dementia were separately pooled and enriched by the magnetic beads-based weak cation exchange chromatography. After trypsin digestion, each enriched CSF was separated and identified by RP-HPLC-ESI-QTOF MS/MS. The authors found 9 proteins uniquely distributed in CSF from probable sCJD group as compared to non-CJD group among which cystatin C 12 and α-1-antichymotrypsin have previously been associated with prion disease. The other identified proteins include α-tubulin, Dickkopfrelated protein 3, gelsolin isoform a precursor, neuronal tissue-enriched acidic protein, proteolipid protein, secreted phosphoprotein 1 and 17 kda cyclophilin A. However, when interpreting these findings, one should bear in mind two major limitations of this study. Firstly, the study did not include quantitative differences between sCJD and non-CJD, and there is a possibility that some clinically relevant peptides are missed. Secondly, there is a possibility of misdiagnosis in each patient group as sCJD patients enrolled in the study were probable sCJD, and there were no autopsy for all patients in non-CJD. Therefore, further studies are needed to determine clinical value of the results presented in this study in terms of CJD diagnosis or pathogenesis.
Summary and Conclusion
Peptides as disease biomarkers in body fluids are more favourable in clinical setting than the full-length protein markers, as they are soluble, easy to handle and can be detected by different biophysical methods and immunoassays. Peptidomics approach to analysis of body fluids, which entails peptide enrichment coupled to mass spectrometric analysis by MALDI-TOF MS and LC-MS/MS, has emerged as a novel tool for biomarker discovery. Growing number of publications speak in favour of significant discriminatory power and sensitivity of this technology, which along with its high-throughput capacity could make peptidomics a method of choice in routine screening procedures, where large number of clinical samples have to be processed in due time. Peptide biomarkers can be used either as a measure of drug efficacy or as indicator of particular disease stage to help determine the patient-specific doses. Therefore, it is reasonable to believe that peptidomics holds the potential for fostering translational research.
Early disease diagnosis is one of the preconditions for successful treatment outcome. Clinical practice has shown so far that single biomarkers are often of limited diagnostic value. A preferred option for increasing the specificity and sensitivity of screening procedures would be to use a panel of biomarkers, such as novel peptide biomarkers in combination with common clinical biomarkers or additional biochemical parameters, e.g. glycosylation status. The latter may particularly prove efficient for cancer detection, as cancer development is accompanied by the changes in cellular glycosylation, and alterations of the N-glycome in body fluids such as serum could provide novel tumour biomarkers [75] .
Although peptidomics has already delivered promising results in the fields of cancer and neurodegeneration, interpretation of these results in clinically meaningful way still poses a big challenge. Future work in peptidomics should focus on clinical validation studies of novel peptide biomarkers in large and well-defined patient cohorts, and optimisation of peptidomics technologies and procedures for routine clinical application. The latter should also include standardisation of protocols for sample collection, handling and storage as to increase reproducibility and reliability of peptidomics analyses.
